Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)

BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL‐17A, has been shown to have significant efficacy and a favourable safety profile in the treatment of moderate‐to‐severe psoriasis and psoriatic arthritis. OBJECTIVE: To assess the efficacy and safety of secuki...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Eur Acad Dermatol Venereol
Hlavní autoři: Bissonnette, R., Luger, T., Thaçi, D., Toth, D., Lacombe, A., Xia, S., Mazur, R., Patekar, M., Charef, P., Milutinovic, M., Leonardi, C., Mrowietz, U.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2018
Témata:
Psoriasis
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6175198/
https://ncbi.nlm.nih.gov/pubmed/29444376
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.14878
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky